KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Capital Expenditures: 2012-2023

Historic Capital Expenditures for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2023 value amounting to $668,000.

  • Travere Therapeutics' Capital Expenditures was N/A to $140,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $257,000, marking a year-over-year change of. This contributed to the annual value of $668,000 for FY2023, which is 249.74% up from last year.
  • Travere Therapeutics' Capital Expenditures amounted to $668,000 in FY2023, which was up 249.74% from $191,000 recorded in FY2022.
  • In the past 5 years, Travere Therapeutics' Capital Expenditures ranged from a high of $6.8 million in FY2020 and a low of $191,000 during FY2022.
  • For the 3-year period, Travere Therapeutics' Capital Expenditures averaged around $2.0 million, with its median value being $668,000 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 3,370.26% in 2020, then crashed by 96.26% in 2022.
  • Over the past 5 years, Travere Therapeutics' Capital Expenditures (Yearly) stood at $195,000 in 2019, then surged by 3,370.26% to $6.8 million in 2020, then fell by 24.62% to $5.1 million in 2021, then crashed by 96.26% to $191,000 in 2022, then skyrocketed by 249.74% to $668,000 in 2023.